CAJ | 학술논문

目的：系统地综述中国多发性骨髓瘤（MM）的治疗现状及药物经济学研究。方法：通过检索国内数据库，对现有已公开发表的相关文献和出版物，从治疗现状和药物经济学研究方面进行汇总、梳理、分析。结果与结论：现有已公开发表的文献均显示随着MM治疗指南的发展和新药的上市，我国MM治疗也有了很大进展。但由于目前诊断及预后评估体系缺乏广泛应用，MM流行病学、疾病负担、新药以及自体移植应用之后生存获益的具体数据和相应的药物经济学研究数据缺乏，中国MM治疗仍面临较大挑战。
목적：계통지종술중국다발성골수류（MM）적치료현상급약물경제학연구。방법：통과검색국내수거고，대현유이공개발표적상관문헌화출판물，종치료현상화약물경제학연구방면진행회총、소리、분석。결과여결론：현유이공개발표적문헌균현시수착MM치료지남적발전화신약적상시，아국MM치료야유료흔대진전。단유우목전진단급예후평고체계결핍엄범응용，MM류행병학、질병부담、신약이급자체이식응용지후생존획익적구체수거화상응적약물경제학연구수거결핍，중국MM치료잉면림교대도전。
Objective: To systematically review on the current situation of and pharmacoeconomic researches on multiple myeloma (MM) treatment in China. Methods: Based on literatures and publications, this study employed a descriptive research to summarize and analyze the related data. Result and Conclusion: With updated NCCN clinical practice guidelines and new medicines coming into markets, a great progress has been made in the treatment of MM in China. But it is still facing signifi cant challenges because of lacking widely used diagnosis and prognosis evaluation system, epidemiological data, disease burden analysis, survival benefit and corresponding cost effectiveness evaluation on new drugs and autologous stem cell transplantation, and high-quality and comprehensive pharmacoeconomic researches.